Verve Therapeutics

VERV · NASDAQ

Price unavailable right now.

No price history for this range.

VERV analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jul 24, 2025

Bull case

Verve Therapeutics, Inc. is positioned to revolutionize the treatment of cardiovascular disease through its novel gene-editing medicines, reflecting a paradigm shift from chronic to single-course therapies that promise enhanced patient adherence and lower healthcare costs. The company holds a strong balance sheet with $540 million in cash, providing a financial runway into mid-2027, which supports its ongoing research and development efforts in promising pipelines such as PCSK9, ANGPTL3, and LPA. Additionally, the recent licensing agreement with BEAM, providing access to advanced base editing technology, exemplifies the growing pharmaceutical interest in gene editing and positions Verve favorably within the competitive landscape.

Bear case

Verve Therapeutics Inc reported a net loss of $0.58 per share in its 4Q24 earnings, with a projected full-year 2025 net loss of $2.38 per share, indicating ongoing financial challenges and a non-revenue generating status. The company's early-stage programs and the lack of imminent catalysts raise concerns about its ability to advance candidates through clinical assessments, alongside significant regulatory hurdles associated with gene-editing technologies for cardiovascular disease. Additionally, investors face speculative risks related to stock price volatility and potential dilution, further complicating the outlook for Verve Therapeutics's stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.